SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-000705
Filing Date
2024-01-02
Accepted
2024-01-02 16:23:02
Documents
15
Period of Report
2024-01-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d700083d8k.htm   iXBRL 8-K 36123
2 EX-99.1 d700083dex991.htm EX-99.1 162002
6 GRAPHIC g700083g92f17.jpg GRAPHIC 30689
7 GRAPHIC g700083g94h33.jpg GRAPHIC 9544
  Complete submission text file 0001193125-24-000705.txt   402995

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA implq-20240102.xsd EX-101.SCH 2498
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE implq-20240102_lab.xml EX-101.LAB 18698
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE implq-20240102_pre.xml EX-101.PRE 11674
9 EXTRACTED XBRL INSTANCE DOCUMENT d700083d8k_htm.xml XML 3895
Mailing Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. W SUITE 260 SEATTLE WA 98119 206-568-1466
IMPEL PHARMACEUTICALS INC (Filer) CIK: 0001445499 (see all company filings)

IRS No.: 263058238 | State of Incorp.: DE | Fiscal Year End: 0426
Type: 8-K | Act: 34 | File No.: 001-40353 | Film No.: 24502744
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)